Buksa M
Klinika za bolesti srca, Klinicki centar Univerziteta u Sarajevu.
Med Arh. 2000;54(2):103-6.
Left ventricle systolic dysfunction and congestive heart failure after AMI are still a great problem in cardiology. Introduction of angiotensin converting enzyme (ACE) inhibitors after AMI has been a new step in therapy of the left ventricle systolic disfunction. Some long term studies have proved influence of ACE inhibitors on reduction of mortality, severe congestive heart failure (CHF), and reinfarction. The importance of administration of a remedy once daily has been emphasized, and the pharmacokinetics and pharmacodynamics of trandolapril in the left ventricle dysfunction and CHF has been described. TRACE study proved influence of long-term once daily administration of trandolapril on significant reduction of total and cardiovascular mortality, reduction of sudden death, reduction of severe and resistant CHF and reduction or relay of reinfarction. A good risk/benefit ratio has been found.
急性心肌梗死后左心室收缩功能障碍和充血性心力衰竭仍是心脏病学中的一大难题。急性心肌梗死后引入血管紧张素转换酶（ACE）抑制剂是治疗左心室收缩功能障碍的新进展。一些长期研究已证实ACE抑制剂对降低死亡率、严重充血性心力衰竭（CHF）和再梗死有影响。已强调每日服用一次药物的重要性，并描述了群多普利在左心室功能障碍和CHF中的药代动力学和药效学。TRACE研究证实，长期每日一次服用群多普利可显著降低总死亡率和心血管死亡率，降低猝死率，减轻严重和顽固性CHF，并减少或延缓再梗死。已发现其具有良好的风险/效益比。
